Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results (S2.008)

Key Points

• The study aims to evaluate the safety and efficacy of riliprubart over a 76-week period in patients with CIDP.
• Conducted as a phase two trial with a focus on riliprubart administration.
• All participants were monitored for safety and efficacy during the 76-week duration.
• Efficacy of riliprubart was confirmed, showing significant improvement in CIDP symptoms.
• Safety profile remained favorable throughout the 76-week treatment period.